Author Correction: Multiparameter prediction of myeloid neoplasia risk

Affiliations

• ¹ Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
• ² Department of Haematology, University of Cambridge, Cambridge, UK.
• ³ Department of Biochemistry and Molecular Biology, Universidad de Oviedo, Oviedo, Spain.
• ⁴ Epidemiology and Cancer Statistics Group, University of York, York, UK.
• ⁵ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
• ⁶ Section of Translational Epidemiology, Division of Population Health Sciences, Bristol, Medical School, University of Bristol, Bristol, UK.
• ⁷ Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
• ⁸ Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
• ⁹ Division of Artificial Intelligence in Oncology, DKFZ, Heidelberg, Germany.
• ¹⁰ Haematological Malignancy Diagnostic Service, St James's Hospital, Leeds, UK.
• ¹¹ Department of Haematology, Leeds Teaching Hospitals, Leeds, UK.
• ¹² Department of Molecular Medicine, University of Pavia, Pavia, Italy.
• ¹³ Department of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
• ¹⁴ Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. pmquiros@ispasturias.es.
• ¹⁵ Department of Haematology, University of Cambridge, Cambridge, UK. pmquiros@ispasturias.es.
• ¹⁶ Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain. pmquiros@ispasturias.es.
• ¹⁷ Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. gsv20@cam.ac.uk.
• ¹⁸ Department of Haematology, University of Cambridge, Cambridge, UK. gsv20@cam.ac.uk.
• ¹⁹ Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK. gsv20@cam.ac.uk.